Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial by Howard, DR et al.
STUDY PROTOCOL Open Access
Chemotherapy plus Ofatumumab at
Standard or Mega dose in relapsed CLL
(COSMIC) trial: study protocol for a phase II
randomised controlled trial
Dena R. Howard1*, Talha Munir2, Anna Hockaday1, Andy C. Rawstron3, Laura Collett1, Jamie B. Oughton1,
David Allsup4, Adrian Bloor5, David Phillips5 and Peter Hillmen2
Abstract
Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination
immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy
in fit patients, but there is limited evidence regarding the optimal treatment of patients after relapse. Ofatumumab as
monotherapy has been proven to be effective in the treatment of relapsed, refractory CLL, and as it is not myelotoxic,
it is an ideal drug to combine with chemotherapy. However, the optimal dose of ofatumumab in this setting is not
known. The Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial will assess the
efficacy and safety of standard and high (mega) doses of ofatumumab combined with bendamustine or a combination
of fludarabine and cyclophosphamide to determine which, if either, schedule should progress to a phase III trial.
Methods/design: COSMIC is a phase II, multi-centre, randomised, open, parallel group trial for patients with relapsed
CLL who are not refractory to fludarabine-based chemotherapy. Participants will be randomised to receive either
standard dose or mega dose ofatumumab. Both doses will be given in combination with either bendamustine or
fludarabine and cyclophosphamide chemotherapy backbone. The primary objective is to assess the proportion of
participants achieving a complete remission following therapy with the two treatment arms (mega versus
standard), as assessed at 3 months post treatment. The treatment groups will be assessed independently to determine
whether the level of response is acceptable in relation to pre-specified criteria. If both treatment groups show an
acceptable level of response, selection criteria will be used to determine which to take forward to a confirmatory
phase III trial. A key secondary objective is to assess the dynamics of minimal residual disease (MRD) levels in
relapsed disease. Eighty-two participants are planned to be recruited from 18 research centres in the UK.
Discussion: Currently there is limited evidence regarding the optimal treatment of patients with relapsed or refractory
CLL, and so suitable therapies are urgently needed. The COSMIC trial will identify whether ofatumumab given
in combination with chemotherapy is safe and effective in this population, and will identify the optimal doses
for further investigation.
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Background
Chronic lymphocytic leukaemia (CLL)
CLL is the most common adult leukaemia, affecting be-
tween 1.0 and 5.0 per 100,000 population [1]. The inci-
dence of CLL increases with age, and twice as many
men are affected as women. CLL arises as a result of the
clonal proliferation of B cells and is diagnosed by the
pattern of expression of various cell surface antigens on
the CLL cells. Patients most commonly present with
lymphocytosis, lymphadenopathy, splenomegaly and
systematic symptoms, such as fatigue, weight loss and
malaise. The clinical course of CLL is highly variable
with a median survival from diagnosis in the region
of 7 years, with the survival being significantly worse
for patients with more advanced disease.
Therapy for relapsed CLL
Over the few years prior to designing the Chemotherapy
plus Ofatumumab at Standard or Mega dose in relapsed
CLL (COSMIC) trial there were substantial improve-
ments in CLL treatment. First line therapy moved away
from monotherapy using chlorambucil towards combin-
ation immunochemotherapy such as fludarabine, cyclo-
phosphamide and rituximab (FCR), following evidence
from large randomised trials [2]. FCR was approved by
the National Institute for Health and Care Excellence
(NICE) [3]; therefore, every patient deemed fit enough
for intensive first line therapy can receive FCR in the
UK. This has resulted in an improvement in response
rates and survival outcomes.
The treatment of relapsed and refractory CLL is in-
creasingly difficult, as the choice of treatment de-
pends on a variety of factors such as prior therapy,
co-morbidities, length of remission and the presence
of biological adverse prognostic factors. With the
relatively recent introduction of FCR to front line
therapy there is no evidence regarding the optimal
treatment of patients after relapse following FCR.
Therapies are needed for this group of patients, since
increasing numbers of patients will be relapsing after
FCR in the future.
For patients who have not previously received fludara-
bine combinations or who have responded to them with
a relatively durable remission, fludarabine combinations
are an option in this setting. Bendamustine (B) has also
become widely used in the treatment of relapsed CLL,
where it is felt to be preferable in those patients who are
not fit for fludarabine.
Other alternatives for patients with fludarabine-
refractory disease or with shorter remissions include
monotherapy with antibodies like alemtuzumab and ofa-
tumumab, combination chemotherapy and possibly allo-
geneic stem cell transplantation.
Rationale for therapeutic study
Ofatumumab (Arzerra®) is an anti-CD20 antibody which,
as a monotherapy, has been demonstrated to be effective
in CLL refractory to fludarabine and either unsuitable
for, or refractory to, alemtuzumab [4]. More than 50 %
of patients with refractory CLL respond to single agent
ofatumumab given at high doses (total dose 22.3 g) [4],
and this dose is now approved by the Food and Drug
Administration (FDA) and European Medicines Agency
(EMA) in this setting. The licensed dose of ofatumumab
when given as a single agent includes high dose intensity
in the first 8 weeks of therapy, with weekly doses of
2000 mg per infusion [4].
The combination of monoclonal antibodies, such as
ofatumumab, with chemotherapy has been demonstrated
to be effective for a variety of lymphoproliferative disor-
ders, including CLL, with clear synergy between the two
treatment modalities. Ofatumumab given at lower doses
(total dose 6.3 g) leads to high response rates, when
combined with FC, in previously untreated patients with
CLL [5]. Therefore, there is a strong rationale to include
the combination of ofatumumab and FC at this lower
dose within a study in a relapsed setting. The higher ap-
proved dose of 22.3 g has been proven to be deliverable
and effective, and since the majority of the ofatumumab
is given in the first 8 weeks of therapy, and as it is not
myelotoxic, combining ofatumumab with the standard
FC chemotherapy at this dose is also an appealing pro-
posal. Therefore, the trial is designed to assess standard
(6.3 g) dose ofatumumab and mega (22.3 g) dose ofatu-
mumab given in combination with FC.
During recruitment, a major protocol amendment was
implemented to allow the chemotherapy backbone to in-
clude bendamustine (B) instead of FC, at the discretion
of the treating clinician. This was in response to chan-
ging clinical practice and in order to open the trial to as
many patients as possible without compromising the
trial design. Bendamustine has been used in combination
with ofatumumab in phase II studies for patients with
both previously untreated [6] and relapsed CLL [6, 7].
The results of these studies demonstrated that ofatumu-
mab in combination with bendamustine is an effective
and tolerable therapy, providing high response rates,
with an acceptable safety profile for patients with re-
lapsed CLL. In addition, the combination of bendamus-
tine with rituximab seems to have similar efficacy in
comparison with FC plus rituximab in the relapsed/re-
fractory setting [8], indicating that the change to include
bendamustine in COSMIC would not be expected to
have a large effect on the response rate.
This trial has therefore been designed as a randomised
phase II trial in patients with relapsed CLL, who are not
fludarabine refractory, in order in order to assess the re-
sponse rates of standard (6.3 g) dose ofatumumab and
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mega (22.3 g) dose ofatumumab, when given in combin-
ation with FC/B. The trial is required to determine
which, if any, schedule shows adequate efficacy and
should be pursued in larger phase III trials.
Methods/design
Trial aims and objectives
The aim of the COSMIC trial is to assess the efficacy of
standard dose and mega dose ofatumumab in combin-
ation with chemotherapy (bendamustine, or fludarabine
and cyclophosphamide) in patients with relapsed CLL.
The trial will allow the assessment of which schedule, if
any, is acceptable in terms of response rate, eradication
of detectable minimal residual disease (MRD) and tox-
icity and should continue to be investigated within a
phase III trial setting.
The primary objective is to assess the rate of complete
remission (CR or CR(i) [CR with incomplete marrow re-
covery]) as defined by the International Workshop on
CLL (iwCLL) criteria [9], following therapy with Stand-
ard Of-FC/B and Mega Of-FC/B.
Secondary objectives are to assess the following: pro-
portion of participants achieving undetectable MRD;
overall response rates as defined by iwCLL criteria;
progression-free survival; overall survival; time to MRD
relapse in MRD-negative participants; dynamics of MRD
relapse and its association with disease progression and
survival; and safety and toxicity.
Trial design
This is a phase II, multi-centre, randomised, open, paral-
lel group trial for patients with relapsed CLL who are
not refractory to fludarabine-based chemotherapy. Pa-
tients with relapsed CLL who require therapy by con-
ventional criteria will be randomised to either standard
dose ofatumumab (6.3 g in total) or high dose ofatumu-
mab (22.3 g in total). All participants will also concur-
rently receive a chemotherapy backbone of either
6 cycles of bendamustine (B) or fludarabine and cyclo-
phosphamide (FC). The choice of backbone therapy
regimen must be made prior to randomisation by either
the treating clinician or the patient, and will be recorded
at the point of randomisation. The trial treatment period
is approximately 6 months. A schedule of enrolment, in-
terventions and assessments is provided in Table 1, and
a populated Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) checklist for this
manuscript is also provided (Additional file 1).
Trial population
Patients who are eligible for the trial must be at least
18 years old, have CLL requiring therapy, have under-
gone at least one regime of chemotherapy previously
and have a life expectancy of at least 12 weeks. The
patient must also be capable of giving written consent,
be considered fit enough to receive fludarabine-based or
bendamustine chemotherapy and have a World Health
Organisation (WHO) performance status (PS) of 0, 1 or 2.
Patients with any of the following characteristics are
excluded from the trial: refractoriness to the planned
chemotherapy backbone (FC/B); deletion of chromo-
some 17p on fluorescence in situ hybridisation (FISH);
previous treatment with ofatumumab either alone or in
combination with chemotherapy; previous toxicity to the
planned chemotherapy backbone (FC/B); active infec-
tion; other severe, concurrent diseases or mental disor-
ders that could interfere with their ability to participate
in the study; creatinine clearance of less than 30 mL/
min for fludarabine or less than 10 mL/min for benda-
mustine; pregnant or lactating women, or women/men
who are capable of conceiving children and who are un-
willing to use appropriate medically approved contracep-
tion during and for 12 months after receiving treatment;
current active hepatic or biliary disease (with the excep-
tion of patients with Gilbert's syndrome, asymptomatic
gallstones, liver metastases or stable chronic liver disease
per investigator assessment); treatment with any known
non-marketed drug substance or experimental therapy
within 5 terminal half-lives or 4 weeks prior to enrol-
ment, whichever is longer, or currently participating
in any other interventional clinical study; other malig-
nancy within 2 years, except completely resected non-
melanoma skin cancer or successfully treated in situ
carcinoma; prior treatment with anti-CD20 monoclo-
nal antibody or alemtuzumab within 3 months prior
to start of therapy; or chronic or current infectious disease
requiring systemic antibiotics, antifungal or antiviral treat-
ment such as, but not limited to, chronic renal infection,
chronic chest infection with bronchiectasis, tuberculosis
and active hepatitis C.
Sample size
Eighty-two participants will be randomised to either
Standard Of-FC/B or Mega Of-FC/B. The A’Hern exact
one-stage design [10] is proposed to assess the efficacy
of each treatment arm based on complete remission to
treatment. Should both dosing schedules be deemed
worthy of further investigation, selection criteria, based
on observing a clinically significant difference in
complete remission rates, will be applied to determine
which treatment to take forward to a phase III trial. The
sample size of 37 participants per arm has been inflated
by 10 % to allow for participants who withdraw or who
do not reach the primary endpoint. Participants who are
randomised, but do not receive any of the study treat-
ment, will be replaced.
Based on the results from the NCRI CLL201 trial [11],
where 15.4 % of participants on the FCM arm achieved
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Table 1 Schedule of enrolment, interventions and assessments
Eligibility
screening
Randomisation Baseline Start of
therapy
After 3 cycles
of therapy
At end of
therapy
3 months
post therapy
12, 18 and 24 months
post randomisation
After 24 months
post randomisation
Annual
follow-up
Enrolment
Eligibility screening X
Informed consent X
Medical history X
Local chemotherapy decision (FC or B) X
Randomisation X
Intervention
Standard Of-FC/B
Mega Of-FC/B
Assessments
CT scan X X Xa
Assessment of disease X X X X
Peripheral blood for MRDb X X Xc Xc Xc
Bone marrow aspirate for MRDb X X
Performance status X X X X X X
Laboratory tests (haematology) X X X X X X
Laboratory tests (biochemistry) X X X X
Body surface aread X X
ARs and SAEs From randomisation until 30 days after the last dose of treatment
SARs and SUSARs From randomisation until the end of the trial
Survival status X
Standard Of-FC/B standard dose ofatumumab + fludarabine and cyclophosphamide/bendamustine, Mega Of-FC/B mega dose ofatumumab + fludarabine and cyclophosphamide/bendamustine, MRD minimal residual
disease, AR adverse event, SAE serious adverse event, SAR serious adverse reaction, SUSAR suspected unexpected serious adverse reaction
aIf appropriate clinically
bTested centrally
cTaken on a 3-monthly basis until five consecutive MRD positive results
dBefore each cycle of therapy and dose changed if greater than 10 % change from baseline
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a CR or CR(i) after treatment, it was agreed that a
complete remission rate of less than this would be con-
sidered unacceptable. It is felt that a response rate of
33 % or greater would be deemed clinically effective.
With 80 % power and a one-sided type I error rate of
5 % for incorrectly determining a schedule worthy of
further consideration when in fact the response rate is
unacceptably low, 10 complete remissions would be re-
quired from 37 participants (95 % confidence interval
(CI) 15.4–43.0 %) in order for either treatment to be
deemed acceptable to be investigated in a larger trial.
Under this design, a particular arm will be a failure if
9/37 (24.3 %) or fewer patients achieve a complete re-
mission. In the NCRI CLL201 trial, the 95 % CI for
the complete remission rate with fludarabine, cyclophos-
phamide, mitoxantrone and rituximab (FCM-R) was
25.5–61.0 %, so these treatments would only be deemed a
failure if they lie below the confidence interval for the re-
sponse rate achieved in a similar population with FCM-R.
If both schedules’ responses successfully exceed the
efficacy boundaries, selection criteria following the
methodology of Sargent and Goldberg [12] will be
implemented. If there are less than 3 responses (8 %)
difference observed between the arms, the trial will
be declared statistically ambiguous, and alternative se-
lection criteria will be used to select the schedule for
further investigation. Otherwise, the schedule with the
better observed response rate will be recommended
to be taken forward. With 37 participants per arm,
and assuming that the correct arm would be selected
50 % of the time by chance if the outcome is statistically
ambiguous, selection probabilities are estimated based on
an assumed complete remission rate of 27 % in the arm
with the poorest response rate. If there is an observed dif-
ference of 3 responses, there is 72 % probability of cor-
rectly identifying the schedule if the true difference
between the two schedules is 8 % (3 responses), 80 %
probability when the true difference is 12 % (4 responses)
and this probability rises as the true difference increases.
The final decision on the schedule for further inves-
tigation will be made by the Trial Steering Committee
(TSC) in conjunction with the Trial Management
Group (TMG), after considering the difference in
complete remission rates, safety and tolerability, costs
and MRD levels.
Recruitment and consent
Participants will be recruited from approximately 18
research centres within the UK under the guidance of
the NCRI (National Cancer Research Institute) CLL
sub-group. The recruitment target requires 82 partici-
pants to be recruited into the trial, 41 in each treat-
ment group. The trial opened to recruitment in
October 2012 and is due to close in April 2016.
Patients will be approached during standard clinic
visits for management of CLL and provided with verbal
and written details about the trial. Informed consent will
be collected by principal investigators at the participat-
ing hospitals. Participants will also be approached for
the UK CLL Trials Biobank as discussed in the subse-
quent section on sub-studies.
Randomisation
Following confirmation of eligibility and consent, par-
ticipants will be randomised into the trial by an
authorised member of staff at the trial research site
(Fig. 1). Randomisation will be performed centrally
using the Leeds Clinical Trials Research Unit (CTRU)
automated 24-hour telephone registration and ran-
domisation system. Participants will be randomised
on a 1:1 basis to receive either Standard Of-FC/B or
Mega Of-FC/B. The choice of FC or B will be chosen
prior to randomisation by the treating clinician or the
participant. Participants are informed of their treat-
ment allocation in this open study.
A computer-generated minimisation program that in-
corporates a random element will be used to ensure
treatment groups are well balanced for the following
participant characteristics: previous therapy containing a
purine analogue such as fludarabine or bendamustine
(Yes or No); age (≤65 or >65); gender; duration of previ-
ous remission (6–24 months or >24 months); choice of
chemotherapy (FC or B).
Protecting against bias
This trial cannot be blinded due to the different sched-
ules of administration of the doses of ofatumumab.
Treating consultants need to be fully aware of the drugs
being administered to be able to treat reactions to treat-
ment accordingly. The trial will use an independent ran-
domisation service, and analyses will be on an intention-
to-treat basis. The trial is administered by the Chief and
Principal Investigators and the CTRU in accordance
with Good Clinical Practice (GCP) guidelines. The pri-
mary endpoint response to treatment will be blindly
assessed by an independent panel. Response will be
assessed using the standard iwCLL criteria [9]. The as-
sessment of response in the bone marrow for MRD will
be centralised in a single laboratory, therefore providing
standardisation for all assessments. So that the backbone
chemotherapy will not be influenced by the outcome of
the randomisation, it will be recorded on the random-
isation system prior to the determination of the treat-
ment allocation.
Baseline assessments
Assessments to be performed prior to the participant
starting treatment are a complete physical examination,
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WHO performance status, serology for hepatitis B and
C, local haematology, biochemistry, a pregnancy test and
an assessment of disease using blood, bone marrow as-
pirate, trephine and computerised tomographic (CT)
scan. See the schedule of enrolment, interventions and
assessments in Table 1.
Intervention
Participants randomised to Standard Of-FC/B will re-
ceive 300 mg of ofatumumab intravenously (IV) on day
1 of cycle 1 and 1000 mg on day 8 of cycle 1 (Fig. 2). For
cycles 2 to 6, they will receive 1000 mg of ofatumumab
(IV) on day 1. Participants randomised to Mega Of-FC/B
will receive 300 mg of ofatumumab (IV) on day 1 of cycle
1, followed by 2000 mg weekly for 8 doses, then 2000 mg
4-weekly for 3 doses. Both treatment groups will also re-
ceive backbone chemotherapy (FC/B).
Those who will receive FC will receive 24 mg/m2/
day of fludarabine (orally) and 150 mg/m2/day of
cyclophosphamide (orally) on days 1 to 5 for cycles 1 to 6.
Cycles of FC are repeated every 28 days for a total of 6 cy-
cles. Compliance with oral administration of FC will be re-
corded in the participant diary card for both trial arms.
Those who will receive B will receive 70 mg/ m2/day on
days 1 to 2 of cycles 1 to 6. Cycles of B are also repeated
every 28 days for a total of 6 cycles. If nausea, vomiting or
diarrhoea occurs with the prior cycle of therapy, FC
should be given via the intravenous route from the next
cycle onwards, due to concerns over drug absorption. The
recommended IV schedule is 25 mg/m2/day of fludarabine
for 3 days and 250 mg/m2/day of cyclophosphamide for
3 days.
Participants are assessed for their suitability for
treatment within 1 week before each cycle according
to standard clinical practice. As a minimum, tests will
be performed to ensure dose reductions are imple-
mented and concomitant medications are adminis-
tered as per protocol.
*NR= No Response, PD=Progressive Disease as per iwCLL guidelines
Mega Of-FC/B (cycles 1-3)
High dose ofatumumab plus either
fludarabine and cyclophosphamide or
bendamustine
Baseline evaluations: Including
CT scan, BM A&T (to HMDS),
BM A, bloods and saliva sample 
(to UKCLL BioBank)
Randomise eligible 
participant
via CTRU telephone system
Standard Of-FC/B (cycles 1-3)
Standard dose ofatumumab plus either
fludarabine and cyclophosphamide or
bendamustine
Therapy completed
Relapsed Chronic Lymphocytic Leukaemia (CLL) requiring therapy
Consent (main trial and BioBank) & Register via CTRU telephone system
6 monthly evaluations from 12 months post randomisation:
Including assessment of disease and 3 monthly MRD assessments until
5 positive MRD samples are received
2 years post randomisation
At disease progression:
Peripheral blood to UK
CLL Biobank
Annual follow-up to death:
Including 3 monthly MRD assessments until 5 positive MRD samples are received
Post Registration assessments to confirm eligibility (including 17p deletion)
Stop 
therapy
NR or
PD*Clinical response Clinical response
Standard Of-FC/B (cycles 4-6)
Standard dose ofatumumab plus either
fludarabine and cyclophosphamide or
bendamustine
Mega Of-FC/B (cycles 4-6)
High dose ofatumumab plus either
fludarabine and cyclophosphamide or
bendamustine
Assessments 3 months post therapy:
Including evaluation of response using iwCLL criteria, BM A&T (to 
HMDS), BM A (to UK CLL BioBank) and CT-scan
Physical examination, haematology, biochemistry
Fig. 1 Trial flow diagram
Howard et al. Trials  (2016) 17:456 Page 6 of 11
The pre-medications are as follows. An analgesic
(equivalent to 1000 mg of paracetamol) and antihista-
mine (equivalent to 10 mg of cetirizine) are administered
prior to all ofatumumab infusions. Corticosteroid infusion
(equivalent to 100 mg of prednisolone) is given for
ofatumumab infusions 1 and 2, and for subsequent
ofatumumab infusions a decreased corticosteroid (equiva-
lent to 0–100 mg of prednisolone) may be given. The cor-
ticosteroid must be given within 30 minutes to
2 hours prior to each ofatumumab infusion. If the
second infusion has been completed without the sub-
ject experiencing any Common Terminology Criteria
for Adverse Events (CTCAE) grade 3 adverse events
(AEs), pre-medication with corticosteroid may be re-
duced or omitted before the third to final ofatumu-
mab infusions at the discretion of the investigator. If
an infusion reaction occurs, the infusion should be
temporarily slowed or interrupted.
The initial rate of the first infusions of 300 mg,
1000 mg or 2000 mg ofatumumab should be 12 mL/
h, and if no infusion reactions occur, the infusion rate
should be increased every 30 minutes to a maximum
of 200 mL/h. For subsequent infusions of 1000 mg/
2000 mg ofatumumab, if the previous infusion was
completed without grade ≥3 infusion-associated AEs,
then the infusion rate can start at 25 mL/h and
should be doubled every 30 minutes to a maximum
of 400 mL/h.
All participants will receive the following concomitant
therapy: co-trimoxazole and acyclovir, to be commenced
prior to therapy and continued until CD4+ counts are
≥200 cells/μL. Participants should receive 300 mg of
allopurinol once daily, and should be prescribed anti-
emetics as per local policy. No concomitant cytotoxic
agents or radiotherapy should be given.
Follow-up
A formal assessment of disease response will be made
3 months after the end of therapy, requiring the collec-
tion of blood, bone marrow aspirate, trephine and a CT
scan as shown in Table 1. In order for the primary end-
point assessment of response to be as robust as possible
and to ensure consistency and accuracy of reporting, the
TMG have selected four CLL clinicians to make inde-
pendent assessments of response (following the iwCLL
criteria [9]), using anonymised data provided for each
participant. Assessors will be blinded to treatment allo-
cation and will not evaluate reports for participants
treated at their centre. Each response assessment is
made by two independent clinicians, and where the out-
comes of the assessments differ, the data is sent to a
third clinician, an independent arbiter, to make a final
decision on response.
Follow-up visits to assess survival and MRD will be
made at 12, 18 and 24 months post randomisation or
until disease progression requiring therapy, if this is be-
fore 24 months post randomisation. Participants will
also be assessed on a 3-monthly basis to monitor MRD
status, which should continue until five consecutive
MRD positive results have occurred. All participants will
be followed up annually for survival until death.
All trial MRD testing will be carried out centrally by the
Haematological Malignancy Diagnostic Service (HMDS)
at Leeds Teaching Hospitals NHS Trust using the harmo-
nised European Research Initiative on CLL (ERIC)
method [13] to ensure standardisation of reporting.
Safety reporting
Adverse reactions (ARs) are any untoward and unin-
tended responses that are related to any dose adminis-
tered of any trial treatment. These can be defined as any
Fludarabine (Oral; 24mg/m2/day; 5 days) + cyclophosphamide (Oral; 150mg/m2/day; 5 days)
OR
Bendamustine (intravenous infusion; 70mg/m2/day; Days 1-2)
Ofatumumab 300mg;    Ofatumumab 1000mg;    Ofatumumab 2000mg
Standard dose ofatumumab plus either fludarabine and cyclophosphamide or
bendamustine (Standard Of-FC/B):
Week 1               5              9             13             17            21
High dose ofatumumab plus either fludarabine and cyclophosphamide or bendamustine
(Mega Of-FC/B):
Week 1               5              9             13             17            21
Fig. 2 Diagrammatic representation of treatment schedule
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unintentional, unfavourable clinical sign or symptom;
any new illness or disease, or the deterioration of exist-
ing disease or illness; or any clinically relevant deterior-
ation in any laboratory assessments or clinical tests. ARs
will be recorded from the start of treatment until 30 days
after the last dose of trial treatment for all participants
and will be evaluated for duration, intensity and causal
relationship with the trial medication according to the
National Cancer Institute Common Terminology Cri-
teria for Adverse Events V4.0 [14] (NCI-CTCAE).
Serious adverse events (SAEs) and serious adverse
reactions (SARs) are events that are fatal or life-
threatening; require or prolong hospitalisation; are sig-
nificantly or permanently disabling or incapacitating;
constitute a congenital anomaly or a birth defect; or
jeopardise the participant and require medical or surgi-
cal intervention to prevent one of the outcomes listed
above. SARs are SAEs that are deemed to be possibly
related to any dose administered of any trial treat-
ment. Suspected unexpected serious adverse reactions
(SUSARs) are SARs which are not listed in the refer-
ence safety information for that medicinal product.
SAEs will be determined and recorded from the start
of treatment until 30 days after the last dose of treat-
ment. SARs and SUSARs should be reported from the
start of treatment and for the duration of the trial.
An independent Data Monitoring and Ethics Com-
mittee (DMEC) will review the safety and ethics of
the trial. The CTRU will prepare detailed unblinded
reports for the DMEC at approximately yearly inter-
vals. Unblinded safety updates are also prepared for
review at 3-monthly intervals whilst participants are
receiving trial treatment.
Data collection
Data will be collected on paper case report forms and
entered into a validated trial database by the CTRU. A
validation check program will be incorporated into the
trial database to verify the data, and discrepancy reports
will be generated for resolution by the investigator. Pri-
ority validations will be incorporated into the validation
programme to ensure that any discrepancies related to
participant rights or safety are expedited to sites for
resolution. Data will be monitored for quality and com-
pleteness by the CTRU. Missing data will be chased until
received, and confirmed as not available or the trial is at
analysis. The CTRU/sponsor will reserve the right to
intermittently conduct source data verification exercises
on a sample of participants, which will be carried out by
staff from the CTRU/sponsor. Source data verification
will involve direct access to participant notes at the par-
ticipating hospital sites and the central collection of cop-
ies of consent forms and other relevant investigation
reports. Data will be held on a secure server at the
University of Leeds and paper case report forms stored
in a locked unit, both of which are accessible only to
authorised trial staff.
Statistical methods and analysis
The CTRU statisticians will be responsible for the statis-
tical analysis, and a final statistical analysis plan will be
written before any analysis takes place.
All analyses will be conducted on the intention-to-
treat (ITT) population, where participants will be in-
cluded according to the treatment arm to which they are
randomised as long as they receive at least one dose of
trial treatment. Participants who are randomised but do
not receive any trial treatments will be replaced, since
this is a phase II trial. A per-protocol (PP) analysis will
also be conducted for the primary endpoint if there are
a considerable number of protocol violators. The safety
population will consist of all participants who received
at least one dose of trial treatment, where participants
will be included according to the treatment they actually
received.
The response endpoints (complete remission, overall
response and MRD response) will be summarised by
treatment group and 95 % confidence intervals reported.
The number and proportion of participants in each indi-
vidual response category will also be reported.
If there are less than 10 complete remissions out of
the first 37 evaluable participants in each treatment arm,
the treatment will be deemed unsuitable to take forward
for further investigation. In the case where both treat-
ment arms are acceptable, the schedule to be taken
forward will be chosen based on the efficacy selection
criteria (a difference of at least three complete remis-
sions). Otherwise, the selection will be determined by
the TMG in discussion with the DMEC and TSC
based on all the available endpoint data and treat-
ment information.
Survival analyses will be carried out for the endpoints
progression-free survival, overall survival and time to
MRD relapse in participants who are MRD negative
when all randomised participants have been followed up
for a minimum of 2 years from randomisation. Survival
will be assessed using Cox regression, adjusting for the
stratification factors, and summarised for each arm using
Kaplan-Meier survival curves and reporting median sur-
vival times.
The MRD results over five time points once MRD is
detectable (MRD positive) will be used to fit a model to
the MRD data to assess the growth pattern of MRD. In-
dividual growth dynamics are assumed to follow the ex-
ponential distribution, where the rate of increase of
MRD levels is assumed to be constant over time. Indi-
vidual growth curves will be fitted for all participants in
order to obtain estimates of the intercept and growth
Howard et al. Trials  (2016) 17:456 Page 8 of 11
parameters for each participant. Assuming independence
between the parameters, they will be incorporated into a
Cox regression analysis on progression-free survival
(PFS) and overall survival (OS) to obtain estimates of
the change in hazard for every unit increase in the
growth parameters, in order to model the relationship
between initial level of MRD once detected, MRD
growth rate and survival.
Safety analyses will summarise all SUSARs, SARs,
SAEs, ARs and treatment-related mortality rates as well
as laboratory changes. Safety data will be presented by
treatment group for the safety population in addition to
relationship to study treatment.
Exploratory analyses may be carried out to assess
whether the following are prognostic of the primary out-
come: randomisation stratification factors; β2-microglob-
ulin; Binet stage; immunoglobulin variable heavy chain
gene (VH) mutation status; and 11q deletion, 13q dele-
tion and trisomy 12 on FISH. These analyses may, by
chance, generate false negative or positive results, and so
those carried out will be interpreted with caution and
treated as hypothesis-generating.
Protocol amendments
The trial opened to recruitment in October 2012 using
version 2 of the protocol. The protocol was amended to
version 4 in April 2014 to include the additional chemo-
therapy backbone of bendamustine in response to chan-
ging clinical practice. This amendment was reviewed
and approved by the sponsor, funder, DMEC, TSC and
Medicines and Healthcare Products Regulatory Author-
ity (MHRA) and REC. Protocol amendments are dissem-
inated to relevant parties by the CTRU.
Sub-studies
Trial participants are also invited to take part in the UK
CLL Trials Biobank at the University of Liverpool. Par-
ticipants are approached at baseline with a separate con-
sent form (REC reference 14/NW/1014), and biological
samples are sent to the University of Liverpool.
Trial organisation and administration
The trial was developed by the COSMIC TMG, with
the support of the UKCLL/NCRI CLL Clinical Trials
Sub-Group. The trial is funded by GlaxoSmithKline
(GSK) and endorsed by the Clinical Trials Awards
and Advisory Committee (CTAAC) of Cancer Research
UK. The trial is sponsored by the Leeds Teaching Hospitals
NHS Trust (R&D Office, 34 Hyde Terrace, Leeds, LS2
9LN), run and co-ordinated by the CTRU, University of
Leeds, and is registered (ISRCTN51382468, EudraCT
Number 2011-000796-14). The trial will be conducted in
accordance with the principles of Good Clinical Practice
(GCP) in clinical trials, as applicable under UK regulations,
the NHS Research Governance Framework and through
adherence to CTRU Standard Operating Procedures
(SOPs). The CTRU and the sponsor have systems in place
to ensure that serious breaches of GCP of the trial protocol
are identified and reported. Ethical approval has been
obtained from the National Research Ethics Service
Committee Yorkshire & The Humber – Leeds East
(reference 11/YH/0260). No additional compensation
for harm was provided for trial participants over that
which is available to NHS patients. Ofatumumab was
only provided for the duration of protocol treatment,
and subsequent treatment is as per standard care.
A core project team, a TMG, a TSC and a DMEC have
been established. The independent DMEC review the
safety and ethics of the trial alongside trial progress, and
the overall direction is overseen by the TSC. Three-
monthly interim safety reports are presented to the
DMEC with a full review annually. The DMEC, in light
of the interim data and of any advice or evidence they
wish to request, will advise the TSC if there are any con-
cerns or reasons that the trial should not continue. The
results of the study will be published in peer-reviewed
journals and will be presented at relevant national and
international conferences. There are no plans to use pro-
fessional writers for presenting the outcomes of this trial.
The CTRU will control the final trial dataset, and any
requests for access will be reviewed by the TMG and
TSC, subject to existing contractual arrangements with
the funder. The protocol, sample case report forms and
participant information are available on a case-by-case
basis as agreed to by the TMG, upon request to the cor-
responding author. A SPIRIT checklist has been pre-
pared for this manuscript.
Discussion
At the time of design, there was limited evidence regard-
ing the optimal treatment of patients with relapsed or re-
fractory CLL, and suitable therapies were urgently needed.
The COSMIC trial is designed to use pre-determined
stopping rules to assess whether standard or high dose
ofatumumab in combination with chemotherapy will be
suitable for carrying out a further phase III trial.
Recruitment has been challenging for COSMIC. The
original trial planned to recruit the required 82 par-
ticipants by March 2014, and to achieve this target
the recruitment period was extended to March 2016.
Recruitment numbers provided during feasibility assess-
ment were significantly higher than observed during trial
recruitment. We believe this was predominantly due to al-
ternative treatments for relapsed CLL becoming available
within clinical trial settings. Ibrutinib and idelalisib both
commenced evaluation within a clinical trials context dur-
ing the lifetime of the trial and have become a more
favourable treatment option to some patients. The TMG,
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TSC and UKCLL/NCRI CLL Clinical Trials Sub-Group
regularly reviewed (at least annually) whether the trial was
still asking a relevant clinical question.
The availability of chemotherapy within the NHS has
posed an additional challenge to executing the trial.
Bendamustine was made available for relapsed CLL
through the Cancer Drugs Fund (CDF) in June 2013 and
was added to the trial protocol in April 2014. This was
carefully considered in terms of the trial design and its
impact on the analysis plan, which was agreed upon with
the oversight committees. The CDF then removed access
to bendamustine in September 2015 for new patients,
which impacted further on recruitment to the trial,
showing the importance of the changing treatment en-
vironment during the lifetime of a trial.
The findings of the COSMIC trial aim to inform the
design and development of a future definitive trial,
which could enhance the treatment of patients with re-
lapsed CLL who are refractory to chemotherapy.
Trial status
The COSMIC trial opened to recruitment in October
2012 and is due to close to recruitment in April 2016.
Additional file
Additional file 1: SPIRIT checklist. (DOC 122 kb)
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